286 related articles for article (PubMed ID: 31700054)
1. Isorhamnetin Alleviates Steatosis and Fibrosis in Mice with Nonalcoholic Steatohepatitis.
Ganbold M; Owada Y; Ozawa Y; Shimamoto Y; Ferdousi F; Tominaga K; Zheng YW; Ohkohchi N; Isoda H
Sci Rep; 2019 Nov; 9(1):16210. PubMed ID: 31700054
[TBL] [Abstract][Full Text] [Related]
2. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
3. Selective Acetyl-CoA Carboxylase 1 Inhibitor Improves Hepatic Steatosis and Hepatic Fibrosis in a Preclinical Nonalcoholic Steatohepatitis Model.
Tamura YO; Sugama J; Iwasaki S; Sasaki M; Yasuno H; Aoyama K; Watanabe M; Erion DM; Yashiro H
J Pharmacol Exp Ther; 2021 Nov; 379(3):280-289. PubMed ID: 34535562
[TBL] [Abstract][Full Text] [Related]
4. Liver X Receptor Inverse Agonist SR9243 Suppresses Nonalcoholic Steatohepatitis Intrahepatic Inflammation and Fibrosis.
Huang P; Kaluba B; Jiang XL; Chang S; Tang XF; Mao LF; Zhang ZP; Huang FZ
Biomed Res Int; 2018; 2018():8071093. PubMed ID: 29670908
[TBL] [Abstract][Full Text] [Related]
5. RLA8-A New and Highly Effective Quadruple PPAR-
Li MH; Chen W; Wang LL; Sun JL; Zhou L; Shi YC; Wang CH; Zhong BH; Shi WG; Guo ZW
J Pharmacol Exp Ther; 2019 Apr; 369(1):67-77. PubMed ID: 30745416
[TBL] [Abstract][Full Text] [Related]
6. Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease.
Cansby E; Nuñez-Durán E; Magnusson E; Amrutkar M; Booten SL; Kulkarni NM; Svensson LT; Borén J; Marschall HU; Aghajan M; Mahlapuu M
Cell Mol Gastroenterol Hepatol; 2019; 7(3):597-618. PubMed ID: 30576769
[TBL] [Abstract][Full Text] [Related]
7. Metabolic and hepatic effects of liraglutide, obeticholic acid and elafibranor in diet-induced obese mouse models of biopsy-confirmed nonalcoholic steatohepatitis.
Tølbøl KS; Kristiansen MN; Hansen HH; Veidal SS; Rigbolt KT; Gillum MP; Jelsing J; Vrang N; Feigh M
World J Gastroenterol; 2018 Jan; 24(2):179-194. PubMed ID: 29375204
[TBL] [Abstract][Full Text] [Related]
8. Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH.
Baandrup Kristiansen MN; Veidal SS; Christoffersen C; Feigh M; Vrang N; Roth JD; Erickson M; Adorini L; Jelsing J
BMC Gastroenterol; 2019 Dec; 19(1):228. PubMed ID: 31883514
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Effect of Gypenosides on Nonalcoholic Steatohepatitis via Regulating Hepatic Lipogenesis and Fatty Acid Oxidation.
Li H; Ying H; Hu A; Hu Y; Li D
Biol Pharm Bull; 2017; 40(5):650-657. PubMed ID: 28458350
[TBL] [Abstract][Full Text] [Related]
10. Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis.
Duparc T; Briand F; Trenteseaux C; Merian J; Combes G; Najib S; Sulpice T; Martinez LO
Am J Physiol Gastrointest Liver Physiol; 2019 Oct; 317(4):G508-G517. PubMed ID: 31460789
[TBL] [Abstract][Full Text] [Related]
11. Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems.
Ross TT; Crowley C; Kelly KL; Rinaldi A; Beebe DA; Lech MP; Martinez RV; Carvajal-Gonzalez S; Boucher M; Hirenallur-Shanthappa D; Morin J; Opsahl AC; Vargas SR; Bence KK; Pfefferkorn JA; Esler WP
Cell Mol Gastroenterol Hepatol; 2020; 10(4):829-851. PubMed ID: 32526482
[TBL] [Abstract][Full Text] [Related]
12. Cathepsin B deficiency ameliorates liver lipid deposition, inflammatory cell infiltration, and fibrosis after diet-induced nonalcoholic steatohepatitis.
Fang W; Deng Z; Benadjaoud F; Yang C; Shi GP
Transl Res; 2020 Aug; 222():28-40. PubMed ID: 32434697
[TBL] [Abstract][Full Text] [Related]
13. Bouchardatine analogue alleviates non-alcoholic hepatic fatty liver disease/non-alcoholic steatohepatitis in high-fat fed mice by inhibiting ATP synthase activity.
Rao Y; Lu YT; Li C; Song QQ; Xu YH; Xu Z; Hu YT; Yu H; Gao L; Gu LQ; Ye JM; Huang ZS
Br J Pharmacol; 2019 Aug; 176(16):2877-2893. PubMed ID: 31113010
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive characterization of metabolic, inflammatory and fibrotic changes in a mouse model of diet-derived nonalcoholic steatohepatitis.
Kim MB; Lee Y; Bae M; Kang H; Pham TX; Hu S; Lee JY; Park YK
J Nutr Biochem; 2020 Nov; 85():108463. PubMed ID: 32891893
[TBL] [Abstract][Full Text] [Related]
15. Vitamin B5 and N-Acetylcysteine in Nonalcoholic Steatohepatitis: A Preclinical Study in a Dietary Mouse Model.
Machado MV; Kruger L; Jewell ML; Michelotti GA; Pereira Tde A; Xie G; Moylan CA; Diehl AM
Dig Dis Sci; 2016 Jan; 61(1):137-48. PubMed ID: 26403427
[TBL] [Abstract][Full Text] [Related]
16. Investigating fibrosis and inflammation in an ex vivo NASH murine model.
Gore E; Bigaeva E; Oldenburger A; Jansen YJM; Schuppan D; Boersema M; Rippmann JF; Broermann A; Olinga P
Am J Physiol Gastrointest Liver Physiol; 2020 Feb; 318(2):G336-G351. PubMed ID: 31905025
[TBL] [Abstract][Full Text] [Related]
17. Nonalcoholic-Fatty-Liver-Disease and Nonalcoholic Steatohepatitis: Successful Development of Pharmacological Treatment Will Depend on Translational Research.
Gottlieb A; Mosthael W; Sowa JP; Canbay A
Digestion; 2019; 100(2):79-85. PubMed ID: 30537758
[TBL] [Abstract][Full Text] [Related]
18. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening.
Ratziu V; Harrison SA; Francque S; Bedossa P; Lehert P; Serfaty L; Romero-Gomez M; Boursier J; Abdelmalek M; Caldwell S; Drenth J; Anstee QM; Hum D; Hanf R; Roudot A; Megnien S; Staels B; Sanyal A;
Gastroenterology; 2016 May; 150(5):1147-1159.e5. PubMed ID: 26874076
[TBL] [Abstract][Full Text] [Related]
19. Calycosin attenuates triglyceride accumulation and hepatic fibrosis in murine model of non-alcoholic steatohepatitis via activating farnesoid X receptor.
Duan X; Meng Q; Wang C; Liu Z; Liu Q; Sun H; Sun P; Yang X; Huo X; Peng J; Liu K
Phytomedicine; 2017 Feb; 25():83-92. PubMed ID: 28190475
[TBL] [Abstract][Full Text] [Related]
20. Ron Receptor Signaling Ameliorates Hepatic Fibrosis in a Diet-Induced Nonalcoholic Steatohepatitis Mouse Model.
Allen J; Zhang J; Quickel MD; Kennett M; Patterson AD; Hankey-Giblin PA
J Proteome Res; 2018 Sep; 17(9):3268-3280. PubMed ID: 30091925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]